论文部分内容阅读
哮喘是一种发病率和死亡率都很高的疾病,有证据表明其流行性和严重度都在不断增加。尽管有β_2-肾上腺能气管扩张剂和可的松等皮质激素之类的有效平喘药在应用,但仍需进一步研究哮喘的病理生理学。早已证明组胺和前列腺素等炎症介质能引起哮喘,但其抑制剂却不能控制哮喘的发作。炎症磷脂介质血小板激活因子(Platelet Activating Factor,PAF)的发现及其很强的生物学作用,提示它可能在几种疾病包括哮喘中起重要作用。最近已发现了几种PAF的拮
Asthma is a disease with a high morbidity and mortality rate, with evidence of increasing prevalence and severity. Despite the availability of potent antiasthmatic drugs such as beta 2 -adrenoceptor and corticosteroids such as cortisone, the pathophysiology of asthma needs to be further studied. It has been shown that inflammatory mediators such as histamine and prostaglandin can cause asthma, but their inhibitors can not control the onset of asthma. The discovery of the inflammatory phospholipid-mediated platelet activating factor (PAF) and its strong biological role suggest that it may play an important role in several diseases, including asthma. Several PAF antagonists have recently been discovered